Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics
(PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to
adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior
therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part
1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and
tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a
confirmatory cohort where patients will be treated at the same doses assessed in Part 2